BioNexus Gene Lab Corp. Deferred Income Tax Expense (Benefit)
BioNexus Gene Lab Corp. (BGLC) reported Deferred Income Tax Expense (Benefit) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-14
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $0.00.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $0.00.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was $0.00.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for fiscal 2024 was $12.30K, a 29.11% decline from fiscal 2023.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for fiscal 2023 was $17.36K.
- BioNexus Gene Lab Corp. deferred income tax expense (benefit) for fiscal 2022 was -$3.90K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-04-14 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $12.30K 10-K · filed 2026-04-14 | |||
| 2023-12-31 | $17.36K 10-K · filed 2025-04-15 | |||
| 2023-06-30 | $15.99K 10-Q · filed 2023-08-16 | |||
| 2022-12-31 | -$3.90K 10-K · filed 2023-03-31 | |||
| 2022-06-30 | $1.62K 10-Q · filed 2023-08-16 | -$12.68K 10-Q · filed 2023-08-16 | ||
| 2021-12-31 | -$26.74K 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $1.24K 10-K · filed 2022-04-06 | -$1.24K 10-K · filed 2021-03-30 | ||
| 2019-12-31 | $4.48K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |